cinvanti
Total Payments
$560,349
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $183,790 | 1 | 0 |
| 2017 | $376,559 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $560,349 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of HTX-019 Administered as an Intravenous Infusion or Injection in Healthy Subjects. | Heron Therapeutics, Inc. | $376,559 | 0 |
| Prospective, Observational Study of the Safety and Tolerability of CINVANTI Administered as an Intravenous Infusion or Injection in Patients Receiving Emetogenic Chemotherapy for Cancer Treatment | Heron Therapeutics, Inc. | $183,790 | 0 |
Top Doctors Receiving Payments for cinvanti
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | West Bend, WI | $560,349 | 3 |
Ad
Manufacturing Companies
- Heron Therapeutics, Inc. $560,349
Product Information
- Type Drug
- Total Payments $560,349
- Total Doctors 0
- Transactions 3
About cinvanti
cinvanti is a drug associated with $560,349 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Heron Therapeutics, Inc..
Payment data is available from 2017 to 2018. In 2018, $183,790 was paid across 1 transactions to 0 doctors.
The most common payment nature for cinvanti is "Unspecified" ($560,349, 100.0% of total).
cinvanti is associated with 2 research studies, including "A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of HTX-019 Administered as an Intravenous Infusion or Injection in Healthy Subjects." ($376,559).